Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
Archives of Medical Science – Atherosclerotic Diseases · 14.03.2025 · 10 (1) · 1-15
DOI: 10.5114/amsad/202298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Medical Science – Atherosclerotic Diseases, online erschienen am 14.03.2025. Verfasst von Georgios S Papaetis und 2 weiteren Autor:innen. Beteiligte Einrichtung: K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, Paphos, Cyprus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
More than 25% of the adult population worldwide and approximately 50–75% of patients with type 2 diabetes are diagnosed with non-alcoholic fatty liver disease. Insulin resistance is one of the most crucial factors underlying its pathogenesis and a significant determinant of its progression to non-alcoholic steatohepatitis. The complex pathophysiology of non-alcoholic fatty liver disease emphasizes the need for combination treatment strategies with drug classes that target different cellular pathways, since no single agent can control all the mechanisms contributing to its development and evolution. Pioglitazone, the main thiazolidinedione in clinical practice, is the only true insulin sensitizing antidiabetic drug in our therapeutic armamentarium for the treatment of patients with type 2 diabetes. Current international practice guidelines recommend PIO as a promising therapy for patients who experience NASH and type 2 diabetes. GLP-1 receptor agonists and SGLT2 inhibitors have shown salutary cardiometabolic and renal effects in patients with type 2 diabetes, as well as beneficial liver activities in those with non-alcoholic fatty liver disease. This review discusses the pathophysiological background for the use of these three drug categories in patients with type 2 diabetes and non-alcoholic fatty liver disease. It also explores thoroughly the combinations of pioglitazone with either GLP-1 receptor agonists or SGLT2 inhibitors, as well as their future role in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, Paphos, Cyprus.
- CDA College, Paphos, Cyprus.
- Department of Biological Sciences, College of Science, University of North Texas, Denton, TX, US.
Zitieren
APA
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025). Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?. Archives of Medical Science – Atherosclerotic Diseases, 10(1), 1-15. https://doi.org/10.5114/amsad/202298
Vancouver
Papaetis GS, Picolos MK, Sacharidou A. Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?. Archives of Medical Science – Atherosclerotic Diseases. 2025;10(1):1-15. doi:10.5114/amsad/202298
BibTeX
@article{Papaetis2025,
author = {Papaetis, Georgios S and Picolos, Michalis K and Sacharidou, Anastasia},
title = {Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?},
journal = {Archives of Medical Science – Atherosclerotic Diseases},
year = {2025},
volume = {10},
number = {1},
pages = {1--15},
doi = {10.5114/amsad/202298}
}
EUVIMED